Vanguard Global Advisers
PHAT icon

Vanguard Global Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

Vanguard Global Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
20,769
-5,742
-22% -$65.5K ﹤0.01% 2458
2026
Q1 		$295K Buy
+26,511
New +$335K ﹤0.01% 2252

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Global Advisers's PHAT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Phathom Pharmaceuticals (PHAT) stake by 22% in Q2 2026, selling an estimated $65.5K and leaving 20,769 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

Vanguard Global Advisers first reported a position in PHAT in Q1 2026 and has held it in 2 quarters since. The position peaked at $295K in Q1 2026. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Vanguard Global Advisers held 20,769 shares of Phathom Pharmaceuticals worth $225K as of Q2 2026.
  • Vanguard Global Advisers sold 5,742 Phathom Pharmaceuticals shares in Q2 2026, an estimated $65.5K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2458 holding.
  • Vanguard Global Advisers first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Phathom Pharmaceuticals position peaked at $295K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.